Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2002Journal of the American Society of Nephrology

First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

KBKlemens BuddeHumboldt-Universität zu BerlinRSRobert SchmouderNovartis (United States)RBR. BrunkhorstKlinikum Region Hannover

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Budde et al. (2002) studied this question.

synapsesocial.com/papers/6a905fbae16d749e8fc92223https://doi.org/10.1681/asn.v1341073
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An immunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis in HL‐601997 · 52 citations
  2. 2Prevention of graft rejection and graft-versus-host reaction by a novel immunosuppressant, FTY 720, in rat small bowel transplantation1997 · 49 citations
  3. 3FTY720: ALTERED LYMPHOCYTE TRAFFIC RESULTS IN ALLOGRAFT PROTECTION2001 · 172 citations
  4. 4A NOVEL IMMUNOSUPPRESSANT, FTY720, WITH A UNIQUE MECHANISM OF ACTION, INDUCES LONG-TERM GRAFT ACCEPTANCE IN RAT AND DOG ALLOTRANSPLANTATION11996 · 291 citations